Iridex (NSDQ:IRIX) announced that it entered into a strategic collaboration with Topcon to develop glaucoma therapy products. Mountain View, Calif.-based Iridex said in a news release that the transaction brings in $19.5 million in cash to the company, providing multiyear funding for strategic growth initiatives, namely those seeking to penetrate the market with Iridex’s non-incisional […]
Topcon Healthcare announced today that it launched its Chronos automated binocular refraction system with SightPilot software. The Topcon Chronos with SightPilot guided refraction software is designed to combine autorefraction, keratometry and subjective refraction in a single device to occupy less than four feet of space, according to a news release. Get the full story at […]
Topcon Healthcare announced today that it launched its new Aladdin-M instrument for eye care measurements in the U.S. Aladdin-M is designed to combine corneal topography, pupillometry and optical biometry to enable objective measurement of corneal curvature, pupil dynamics and axial length metrics, according to a news release. Oakland, N.J.-based Topcon’s system includes software that enables […]
UPDATED with a clarification from IBM Watson Health. Topcon Healthcare Solutions said today that it is a preferred vendor for IBM Watson Health Imaging in support of a transition plan for the Merge Eye imaging platform. IBM Watson plans to discontinue customer support for the Merge Eye Station digital fundus imaging platform and the Merge […]
Topcon Medical Systems said today that its DRI OCT Triton Series system won 510(k) clearance from the FDA. The company’s ocular diagnostic instrument features a built-in retinal camera, eye-tracking and a 1 micron, 1050 nm light source with a scanning speed of 100,000 A-scans/second. Topcon’s touted its system as being able to quickly penetrate ocular […]
NuVasive (NSDQ:NUVA) closed its $80 million pickup of Impulse Monitoring Inc. last week, according to a filing with the federal Securities & Exchange Commission.
The deal, which closed Oct. 7, saw IMI’s shareholders receive nearly $40.5 million in cash and more than 2.3 million shares of NuVasive common stock with an aggregate value of about $40.5 million (per NUVA’s Oct. 6 closing share price of $17.32).